Close
Help
Need Help?



Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer

Submit a Paper



Publication Date: 24 May 2011

Type: Review

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine Insights: Oncology 2011:5 163-169

doi: 10.4137/CMO.S6566

Abstract

Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no standard treatment options available for men with disease progression on docetaxel. In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting. In this review, we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and direction of future therapeutic investigation.


Downloads

PDF  (874.47 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Your Colleagues Say

Quick Links

Follow Us We make it easy to find new research papers.
Email AlertsRSS Feeds
FacebookGoogle+Twitter
PinterestTumblrYouTube

SUBJECT HUBS
Our Testimonials
Publishing in Air, Soil and Water and Water Research was the best experience I have had so far in an academic context.  The review process was fair, quick and efficient.  I congratulate the team at Libertas Academica for a very well managed journal.
Magnus Karlsson (IVL Swedish Environmental Research Institute, Stockholm, Sweden) What Your Colleagues Say